EDIT - エディタス・メディシン (Editas Medicine Inc.)

EDITのニュース

   Why Editas Medicine Stock Is Jumping Today | The Motley Fool  2021/06/28 16:17:15 The Motley Fool
Good news for Intellia was viewed as good news for Editas.
   Why Editas Medicine Stock Is Jumping 13.9% This Week  2021/06/25 10:01:00 The Motley Fool
The company received a go-ahead to enroll kids in a study of its lead gene-editing candidate.
   Enrollment underway in Editas Medicine''s pediatric cohort of EDIT-101 study in inherited retinal disorder  2021/06/23 11:38:36 Seeking Alpha
   Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer  2021/06/15 20:01:00 Intrado Digital Media
CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Companys newly appointed Executive Vice President and Chief Scientific Officer, Mark Shearman, Ph.D., and Senior Vice President and Chief Regulatory Officer, Chi Li, Ph.D. In connection with the appointments, the Editas Medicine Board of Directors approved a stock option grant and a restricted stock unit award to each of Drs. Shearman and Li as inducements material to their entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4). Drs. Shearmans and Lis stock options provide for the purchase of up to 52,718 shares and 44,202 shares, respectively, of Editas Medicine common stock at a price of $38.53 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vest over four years, with 25 percent of the shares vesting on the first anniversary of each individuals employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to their continued service relationship with Editas Medicine through the applicable vesting dates.
   Editas Medicine names new chief science and chief regulatory officers  2021/06/14 13:14:46 Seeking Alpha
   Booming CAGR of 20.8%, CRISPR and CAS Gene Market to Surpass US$ 7,603.8 Million by 2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc  2021/03/23 11:13:10 OpenPR
A new market study on the 2020-2027 CRISPR and CAS Gene Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report
   CRISPR and CAS Gene Market – Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript  2021/03/02 07:34:47 OpenPR
CRISPR and CAS Gene Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu,
   Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results  2021/02/26 16:09:01 Transcript Daily
Editas Medicine (NASDAQ:EDIT) posted its quarterly earnings data on Thursday. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.19), MarketWatch Earnings reports. The company had revenue of $11.42 million during the quarter, compared to analyst estimates of $5.64 million. Editas Medicine had a negative return on […]
   Editas Medicine Is it time to Buy before this week’s earning report Stock market Insights & financial analysis  2021/02/24 15:28:00 Stock Market Daily
Editas Medicine announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Better Buy: CRISPR Therapeutics vs. Editas Medicine  2021/02/05 11:10:00 The Motley Fool
Which of these two hot gene therapy stocks is the better buy?
   Booming CAGR of 20.8%, CRISPR and CAS Gene Market to Surpass US$ 7,603.8 Million by 2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc  2021/03/23 11:13:10 OpenPR
A new market study on the 2020-2027 CRISPR and CAS Gene Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report
   CRISPR and CAS Gene Market – Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript  2021/03/02 07:34:47 OpenPR
CRISPR and CAS Gene Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu,
   Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results  2021/02/26 16:09:01 Transcript Daily
Editas Medicine (NASDAQ:EDIT) posted its quarterly earnings data on Thursday. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.19), MarketWatch Earnings reports. The company had revenue of $11.42 million during the quarter, compared to analyst estimates of $5.64 million. Editas Medicine had a negative return on […]
   Editas Medicine Is it time to Buy before this week’s earning report Stock market Insights & financial analysis  2021/02/24 15:28:00 Stock Market Daily
Editas Medicine announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Better Buy: CRISPR Therapeutics vs. Editas Medicine  2021/02/05 11:10:00 The Motley Fool
Which of these two hot gene therapy stocks is the better buy?

calendar